Sofosbuvir
To view the entire topic, please log in or purchase a subscription.
Official website of the Johns Hopkins Antibiotic (ABX), HIV, Diabetes, and Psychiatry Guides, powered by Unbound Medicine. Johns Hopkins Guide App for iOS, iPhone, iPad, and Android included. Explore these free sample topics:
-- The first section of this topic is shown below --
INDICATIONS
FDA
- Treatment of HCV genotype 1, 2, 3 or 4 as a component of a combination antiviral treatment regimen
- Indicated in patients with hepatocellular carcinoma, those awaiting liver transplantation, and those with HCV/HIV-1 co-infection
NON-FDA APPROVED USES
- In combination with an HCV active antiviral regimen, sofosbuvir’s (SOF) efficacy has been established in patients with HCV genotype 5 and 6
-- To view the remaining sections of this topic, please log in or purchase a subscription --
INDICATIONS
FDA
- Treatment of HCV genotype 1, 2, 3 or 4 as a component of a combination antiviral treatment regimen
- Indicated in patients with hepatocellular carcinoma, those awaiting liver transplantation, and those with HCV/HIV-1 co-infection
NON-FDA APPROVED USES
- In combination with an HCV active antiviral regimen, sofosbuvir’s (SOF) efficacy has been established in patients with HCV genotype 5 and 6
There's more to see -- the rest of this entry is available only to subscribers.